CD137L promotes immune surveillance in melanoma via HLTF regulation
Sign Up to like & getrecommendations! Published in 2025 at "Nature Communications"
DOI: 10.1038/s41467-025-63338-w
Abstract: Immune checkpoint blockers (ICBs) have demonstrated substantial efficacy across various malignancies, yet the benefits of ICBs are limited to a subset of patients. Therefore, it is essential to identify novel therapeutic targets. By integrating multi-omics… read more here.
Keywords: immune checkpoint; cd137l expression; melanoma; cd137l ... See more keywords